The Global Health Body Sounds Concern Over Severe Lack of Weight-Loss Jabs

Fewer than one in 10 individuals who could benefit from obesity jabs like Wegovy are able to get them, states the WHO as it releases its first guidance on the medications.

With in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable access to GLP-1 medication.

According to estimates, over two billion will be living with obesity by 2030 if no action is taken.

"The new guidelines affirms that obesity is a chronic disease that can be addressed with thorough and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are significant barriers to widespread availability to the jabs that can aid individuals in losing significant body mass, says the organization.

Weight-Loss Drug Supply Crisis

Even in the current best projected scenario, the manufacturing of these medications might only reach about 100 million people – less than 10% of eligible patients, per the WHO.

The advice calls on governments and firms to widen availability, via strategies such as voluntary licensing.

A patent on a key compound – the core component of a leading brand – is set to lapse in a number of nations in 2026.

The Way Weight-Loss Jabs Operate

These medications imitate a body's own hormone to reduce digestion speed, reduce hunger and boost satiety so users eat less.

Individuals commonly see weight reduction in the initial weeks of beginning the weekly injections.

Research indicates users may see weight return after a year of discontinuing the treatment, because their normal food cravings come back.

Being carrying excess weight increases your likelihood for experiencing health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.

Obesity concerns individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.